| Followers | 28 |
| Posts | 21765 |
| Boards Moderated | 0 |
| Alias Born | 01/16/2026 |
Wednesday, May 27, 2026 8:00:12 AM
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
May 27, 2026 7:45 AM
PR Newswire (US)
Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholders
MIAMI, May 27, 2026 /PRNewswire/ - Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist investing, today announced that it has acquired 4.9% of the issued and outstanding common stock of BioRestorative Therapies, Inc. ("BRTX" or the "Company").
This ownership stake was acquired in the open market through normal course stock purchases. Kaos Capital believes that BRTX represents a compelling opportunity, as the public vehicle may be better positioned for a strategic pivot into the AI space.
Unfortunately, BRTX shareholders are not currently gaining meaningful value from the existing business. We at Kaos feel that the Company should explore a comprehensive strategic review and consider a pivot into a broader range of AI opportunities.
As a significant shareholder, Kaos Capital is committed to working constructively with the BRTX Board of Directors and management to unlock shareholder value. To that end, we intend to seek an immediate meeting with the Board to discuss the Company's strategy, operations, corporate governance, and potential pathways—including a possible pivot into AI—to enhance value for all shareholders.
We look forward to engaging in a productive dialogue that prioritizes the best interests of BRTX and its shareholders.
About Kaos Capital
Kaos Capital Ltd. is a Miami-based hedge fund with offices in The Bahamas and Toronto, specializing in activist investing, primarily in the Canadian and U.S. markets. Led by Adam Arviv, Kaos Capital seeks to partner with management teams and boards to drive operational improvements and strategic initiatives that maximize long-term shareholder value.
Cautionary Note
This announcement is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. All investments involve risk, and past performance is not indicative of future results. Shareholders should consult their own advisors regarding their individual circumstances.
View original content:https://www.prnewswire.com/news-releases/kaos-capital-announces-acquisition-of-4-9-stake-in-biorestorative-therapies-nasdaq-brtx-302782386.html
SOURCE KAOS Capital
Original: Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
Recent BRTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2026 09:07:05 PM
- Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX) • PR Newswire (Canada) • 05/27/2026 11:45:00 AM
- Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX) • PR Newswire (US) • 05/27/2026 11:45:00 AM
- BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data • GlobeNewswire Inc. • 05/26/2026 03:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 07:30:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 08:31:37 PM
- BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals • GlobeNewswire Inc. • 05/13/2026 03:00:00 PM
- BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 05/07/2026 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/01/2026 08:17:58 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/30/2026 08:10:19 PM
- BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform • GlobeNewswire Inc. • 04/30/2026 02:36:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/27/2026 08:05:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 09:12:57 PM
- BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform • GlobeNewswire Inc. • 04/21/2026 12:00:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/20/2026 09:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/13/2026 09:22:23 PM
- BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform • GlobeNewswire Inc. • 04/07/2026 12:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/03/2026 06:46:20 PM
- BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 08:20:29 PM
- BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 03/19/2026 12:00:00 PM
- BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026 • GlobeNewswire Inc. • 03/05/2026 01:00:00 PM
- BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy • GlobeNewswire Inc. • 03/04/2026 01:00:00 PM
- BioRestorative secures Australian patent protection for ThermoStem® obesity therapy platform • IH Market News • 02/24/2026 03:14:07 PM
